RESUMEN
Objective Toinvestigate MRIIVIM quantitativeassessmentoftheplacentalperfusioncanbeusedtodifferentiate womenwithandwithoutplacentaaccretaintheirthirdtrimester.Methods Thestudypopulationincluded17patientswithplacenta accreta,29patientswithplacentaincretaand16patientswithoutplacentaaccreta.Allwomenunderwentan MRIexaminationincluding anIVIMsequence.Theperfusionfraction(f),pseudodiffusioncoefficient(D?)andstandarddiffusioncoefficient(D)werecalculated. Results Womenwithplacentaaccretaandincretahadasmallerplacentalperfusionfraction (P＜0.05)thanpatientswithoutplacenta accreta,theplacentalperfusionfractiondidn’tdifferedbetweenplacentaaccretaandincreta(P＞0.05).DifferencesofDandD?between thethreegroupswerenotsignificant(P＞0.05).Conclusion Placentaaccretaandincretadifferinplacentalperfusionfractionfrom womenwithoutthedisease.Theperfusionfractioncanbeusedasafeasibleindextoevaluateplacentaperfusion.
RESUMEN
Pre-eclampsia (PE) is a pregnancy disorder that is characterised by severe hypertension and increased risks of foetal and maternal mortality. The aetiology of PE not completely understood; however, maternal nutrition and oxidative stress play important roles in the development of hypertension. The treatment options for PE are currently limited to anti-hypertensive drugs. Punicalagin, a polyphenol present in pomegranate juice, has a range of bioactive properties. The effects of supplementation with punicalagin on angiogenesis and oxidative stress in pregnant rats with induced hypertension were investigated. The pregnant rats were randomly divided into five experimental groups (n=12 per group). Hypertension was induced using an oral dose of NG-nitro-L-arginine methyl ester (L-NAME, 50 mg/kg/day) on days 14–19 of pregnancy. Punicalagin (25, 50 or 100 mg/kg) was given orally on days 14–21 of pregnancy. Punicalagin treatment at the tested doses significantly reduced diastolic, systolic, and mean arterial blood pressure in L-NAME treated rats from day 14. Punicalagin also restored angiogenic balance by increasing the expression of vascular endothelial growth factor and downregulating vascular endothelial growth factor receptor-1/fms-like tyrosine kinase-1. Punicalagin, significantly increased the placental nitric oxide levels as compared to PE group. The increased levels of oxidative stress in rats with PE were markedly decreased by treatment with punicalagin. Punicalagin at the tested doses markedly (p < 0.05) enhanced the placental antioxidant capacity in L-NAME-treated rats. The raised catalase activity observed following L-NAME induction was significantly (p < 0.05) and restored to normal activity levels in punicalagin treatment. Further, 100 mg dose of punicalagin exhibited higher protective effects as compared to lower doses of 25 and 50 mg. This study shows that supplementation with punicalagin decreased blood pressure and oxidative stress and restored angiogenic balance in pregnant rats with induced PE.